Literature DB >> 27585358

Metabolic variations in normal and fibrotic human laryngotracheal-derived fibroblasts: A Warburg-like effect.

Garret Ma1, Idris Samad2, Kevin Motz2, Linda X Yin2, Madhavi V Duvvuri2, Dacheng Ding2, Daryan R Namba2, Jennifer H Elisseeff1, Maureen R Horton3, Alexander T Hillel2.   

Abstract

OBJECTIVES/HYPOTHESIS: Laryngotracheal stenosis (LTS) is a chronic fibrotic disease characterized by fibroblast proliferation, collagen deposition, and matrix remodeling in the lamina propria of the larynx and/or trachea. Current medical therapies are limited by a poor understanding of the effector cell's (fibroblasts) cellular biology and metabolism. The purpose of this study was to compare cellular proliferation, function, and metabolism between normal and LTS-derived fibroblasts in vitro. We hypothesize that LTS-derived fibroblasts will demonstrate aberrant behavior with faster proliferation, increased collagen production, and altered metabolic allocation compared with normal fibroblasts. STUDY
DESIGN: In vitro comparative analysis.
METHODS: Human biopsies of normal and iatrogenic LTS tissue (n = 7) were obtained, and fibroblasts were isolated and cultured in vitro. Cellular proliferation, cellular histology, gene expression, and metabolic analyses were performed. Statistical analyses comparing normal and scar-derived fibroblasts were performed.
RESULTS: LTS fibroblast proliferation rate, cellular surface area, and collagen-1 expression were increased compared to normal fibroblasts. Cellular metabolic analysis of LTS-derived fibroblasts demonstrated reduced oxidative phosphorylation and increased glycolysis/oxidative phosphorylation ratio compared with normal fibroblasts.
CONCLUSIONS: Human iatrogenic LTS-derived fibroblasts demonstrated aberrant behavior when compared with normal fibroblasts. A Warburg-like effect was revealed, suggesting human iatrogenic LTS fibroblasts drive their proliferation with aerobic glycolysis. The distinct metabolism suggests metabolic inhibitors could reduce fibroblast hyperplasia and hypertrophy in LTS and fibrosis in general. LEVEL OF EVIDENCE: NA Laryngoscope, 127:E107-E113, 2017.
© 2016 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Fibrosis; Warburg effect; cellular metabolism; fibroblasts; laryngotracheal stenosis; larynx; mechanistic target of rapamycin

Mesh:

Substances:

Year:  2016        PMID: 27585358      PMCID: PMC5321789          DOI: 10.1002/lary.26254

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  29 in total

Review 1.  Mechanisms of pulmonary fibrosis.

Authors:  Victor J Thannickal; Galen B Toews; Eric S White; Joseph P Lynch; Fernando J Martinez
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  Fibrosis--A Common Pathway to Organ Injury and Failure.

Authors:  Don C Rockey; P Darwin Bell; Joseph A Hill
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

Review 4.  Rapamycin passes the torch: a new generation of mTOR inhibitors.

Authors:  Don Benjamin; Marco Colombi; Christoph Moroni; Michael N Hall
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

5.  NIH Image to ImageJ: 25 years of image analysis.

Authors:  Caroline A Schneider; Wayne S Rasband; Kevin W Eliceiri
Journal:  Nat Methods       Date:  2012-07       Impact factor: 28.547

6.  Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy.

Authors:  Su-Yang Yu; Lei Liu; Pu Li; Jie Li
Journal:  Thorac Cardiovasc Surg       Date:  2012-06-08       Impact factor: 1.827

7.  Posttranscriptional control of T cell effector function by aerobic glycolysis.

Authors:  Chih-Hao Chang; Jonathan D Curtis; Leonard B Maggi; Brandon Faubert; Alejandro V Villarino; David O'Sullivan; Stanley Ching-Cheng Huang; Gerritje J W van der Windt; Julianna Blagih; Jing Qiu; Jason D Weber; Edward J Pearce; Russell G Jones; Erika L Pearce
Journal:  Cell       Date:  2013-06-06       Impact factor: 41.582

8.  Comparative immunohistochemical staining for desmin and muscle-specific actin. A study of 576 cases.

Authors:  S Rangdaeng; L D Truong
Journal:  Am J Clin Pathol       Date:  1991-07       Impact factor: 2.493

9.  Voice quality in laryngotracheal stenosis: impact of dilation and level of stenosis.

Authors:  Alexander T Hillel; Selmin Karatayli-Ozgursoy; James R Benke; Simon Best; Paulette Pacheco-Lopez; Kristine Teets; Heather Starmer; Lee M Akst
Journal:  Ann Otol Rhinol Laryngol       Date:  2014-12-17       Impact factor: 1.547

10.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14
View more
  21 in total

1.  Interferon-γ Treatment of Human Laryngotracheal Stenosis-Derived Fibroblasts.

Authors:  Kevin Motz; Idris Samad; Linda X Yin; Michael K Murphy; Madhavi Duvvuri; Dacheng Ding; Alexander T Hillel
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-11-01       Impact factor: 6.223

2.  Fibroblasts in Hypoxic Conditions Mimic Laryngotracheal Stenosis.

Authors:  Linda X Yin; Kevin M Motz; Idris Samad; Madhavi Duvvuri; Michael Murphy; Dacheng Ding; Alexander T Hillel
Journal:  Otolaryngol Head Neck Surg       Date:  2017-03-28       Impact factor: 3.497

3.  Targeting metabolic abnormalities to reverse fibrosis in iatrogenic laryngotracheal stenosis.

Authors:  Michael K Murphy; Kevin M Motz; Dacheng Ding; Linda Yin; Madhavi Duvvuri; Michael Feeley; Alexander T Hillel
Journal:  Laryngoscope       Date:  2017-09-20       Impact factor: 3.325

4.  Engineering an immunomodulatory drug-eluting stent to treat laryngotracheal stenosis.

Authors:  Madhavi Duvvuri; Kevin Motz; Michael Murphy; Michael Feeley; Dacheng Ding; Andrew Lee; Jennifer H Elisseeff; Alexander T Hillel
Journal:  Biomater Sci       Date:  2019-04-23       Impact factor: 6.843

5.  Incubation of canine dermal fibroblasts with serum from dogs with atopic dermatitis activates extracellular matrix signalling and represses oxidative phosphorylation.

Authors:  Monica Colitti; Bruno Stefanon; Misa Sandri; Danilo Licastro
Journal:  Vet Res Commun       Date:  2022-06-04       Impact factor: 2.459

6.  Inhibition of glutaminase to reverse fibrosis in iatrogenic laryngotracheal stenosis.

Authors:  Hsiu-Wen Tsai; Kevin M Motz; Dacheng Ding; Ioan Lina; Michael K Murphy; Dimitri Benner; Michael Feeley; Jody Hooper; Alexander T Hillel
Journal:  Laryngoscope       Date:  2020-01-06       Impact factor: 3.325

7.  Glutamine Inhibition Reduces Iatrogenic Laryngotracheal Stenosis.

Authors:  Hsiu-Wen Tsai; Ioan Lina; Kevin M Motz; Liam Chung; Dacheng Ding; Michael K Murphy; Michael Feeley; Jennifer H Elisseeff; Alexander T Hillel
Journal:  Laryngoscope       Date:  2021-01-12       Impact factor: 2.970

8.  M2 Macrophages Promote Collagen Expression and Synthesis in Laryngotracheal Stenosis Fibroblasts.

Authors:  Kevin Motz; Ioan Lina; Michael K Murphy; Virginia Drake; Ruth Davis; Hsiu-Wen Tsai; Michael Feeley; Linda X Yin; Dacheng Ding; Alexander Hillel
Journal:  Laryngoscope       Date:  2020-08-17       Impact factor: 3.325

9.  Identifying Phenotypically Distinct Fibroblast Subsets in Type 2 Diabetes-Associated Iatrogenic Laryngotracheal Stenosis.

Authors:  Ioan A Lina; Alexandra Berges; Rafael Ospino; Ruth J Davis; Kevin M Motz; Hsiu-Wen Tsai; Samuel Collins; Alexander T Hillel
Journal:  Otolaryngol Head Neck Surg       Date:  2021-06-15       Impact factor: 3.497

10.  Characterization of Fibroblasts in Iatrogenic Laryngotracheal Stenosis and Type II Diabetes Mellitus.

Authors:  Ioan Lina; Hsiu-Wen Tsai; Dacheng Ding; Ruth Davis; Kevin M Motz; Alexander T Hillel
Journal:  Laryngoscope       Date:  2020-08-28       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.